S151

Core Expertise:
Develop/establish solid IP portfolio / market exclusive strategy. • Drug discovery and development in: o Anti-bacterials, gastrointestinal (IBD, Crohn’s), and cancer immunotherapy mediated by cancer antigen-protein conjugates o Small organic molecules, peptides to glycol-materials (cancer antigens / glycosaminoglycans / glycoproteins).
Previous Companies:
Cubist • Optimer Pharmaceuticals, Inc.